DigestRedComo funciona
Red
/
Empresas
F.
No verificado

F. Hoffmann-La Roche Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaPublicidad/Marketing/Medios de comunicación/Comunicación

149 Comunicados de prensa

Ver todos los comunicados de prensa
24/07/2026
Farmacéutica
Anuncios breves
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
22/07/2026
Farmacéutica
Anuncios breves
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
14/07/2026
Farmacéutica
Anuncios breves
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
13/07/2026
Farmacéutica
Anuncios breves
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
08/07/2026
Farmacéutica
Anuncios breves
Roche receives CE Mark for blood test to identify tuberculosis infection
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
06/07/2026
Farmacéutica
Anuncios breves
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
01/07/2026
Farmacéutica
Anuncios breves
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
29/06/2026
Farmacéutica
Anuncios breves
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
28/06/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
17/06/2026
Farmacéutica
Anuncios breves
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0